Effective June 3, 2015, JINARC™ (tolvaptan) was made commercially available for use in Canada. It is the first treatment in Canada for patients living with autosomal dominant polycystic kidney disease (ADPKD)
The Kidney Foundation of Canada is pleased to have the opportunity each year to celebrate its many volunteers and supporters through its National Recognition Program. Most recently, Foundation representatives had the opportunity to present Alex Lifeson, guitarist with the Canadian band RUSH, with a Public Awareness Award.
Your experiences as a patient, caregiver, researcher and or healthcare professional can help identify the top research priorities in transplantation and donation within the Canadian National Transplant Research Program (CNTRP) in order to improve the treatment and the quality of life of transplanted patients and patients waiting for a transplant. For more details visit www.kidney.ca/surveys.
Your support makes a positive impact in the kidney community! Download our Impact Report 2014 to see how your giving makes a difference.